Indonesia launches $30 million plasma drug program to strengthen health resilience
Indonesia’s health ministry partnered with Takeda Life Sciences on a $30 million plan to build a domestic plasma-derived medicine ecosystem, aiming to secure supplies for rare and chronic diseases.
In Jakarta, the Ministry of Health unveiled a joint venture with Takeda Life Sciences to establish Indonesia’s inaugural plasma-derived medicinal product ecosystem, supported by a $30 million seed fund. The program targets life-saving therapies for conditions such as primary immunodeficiency, hemophilia and other rare diseases, addressing current shortages caused by limited donor readiness and fragmented coordination. Aswardi, head of the ministry’s Working Group on Blood and Immunological Disorders, emphasized the need for public willingness to donate plasma.
Dita Novianti Sugandi Argadireja, director of pharmaceutical production and distribution, called the effort a cornerstone of national health resilience. Under the agreement, Takeda will be authorized to conduct plasma fractionation locally, and a two-year roadmap will see a national plasma bank network and the first processing plant operating by 2027. Health Minister Budi Gunadi Sadikin framed the partnership as a step toward localizing advanced healthcare manufacturing and mitigating global supply-chain risks.
Why it matters
Securing local plasma-derived medicines reduces Indonesia’s dependence on imports and improves treatment access for rare diseases.
In this story
